98 related articles for article (PubMed ID: 8339275)
21. Selective activation of 5'-deoxy-5-fluorouridine by tumor cells as a basis for an improved therapeutic index.
Armstrong RD; Diasio RB
Cancer Res; 1981 Dec; 41(12 Pt 1):4891-4. PubMed ID: 6171343
[TBL] [Abstract][Full Text] [Related]
22. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
23. Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase.
Duch DS; Banks S; Dev IK; Dickerson SH; Ferone R; Heath LS; Humphreys J; Knick V; Pendergast W; Singer S
Cancer Res; 1993 Feb; 53(4):810-8. PubMed ID: 8428362
[TBL] [Abstract][Full Text] [Related]
24. The NAD(P)H:quinone oxidoreductase locus in human colon carcinoma HCT 116 cells resistant to mitomycin C.
Hu LT; Stamberg J; Pan S
Cancer Res; 1996 Nov; 56(22):5253-9. PubMed ID: 8912865
[TBL] [Abstract][Full Text] [Related]
25. Comparison of 5-fluorouracil metabolism in two human gastrointestinal tumor cell lines.
Washtien WL
Cancer Res; 1984 Mar; 44(3):909-14. PubMed ID: 6318987
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes.
Kornmann M; Danenberg KD; Arber N; Beger HG; Danenberg PV; Korc M
Cancer Res; 1999 Jul; 59(14):3505-11. PubMed ID: 10416617
[TBL] [Abstract][Full Text] [Related]
27. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.
Jackman AL; Kimbell R; Aherne GW; Brunton L; Jansen G; Stephens TC; Smith MN; Wardleworth JM; Boyle FT
Clin Cancer Res; 1997 Jun; 3(6):911-21. PubMed ID: 9815766
[TBL] [Abstract][Full Text] [Related]
28. Cytotoxic effects and mechanisms of an alteration in the dose and duration of 5-fluorouracil.
Patel M; Ardalan K; Hochman I; Tian EM; Ardalan B
Anticancer Res; 2003; 23(1A):447-52. PubMed ID: 12680247
[TBL] [Abstract][Full Text] [Related]
29. Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance.
Ogretmen B; McCauley MD; Safa AR
Biochemistry; 1998 Aug; 37(33):11679-91. PubMed ID: 9709006
[TBL] [Abstract][Full Text] [Related]
30. Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients.
Hoshino S; Yamashita Y; Maekawa T; Shirakusa T
Cancer Chemother Pharmacol; 2005 Dec; 56(6):648-52. PubMed ID: 15959779
[TBL] [Abstract][Full Text] [Related]
31. Alternate splicing of the rTS gene product and its overexpression in a 5-fluorouracil-resistant cell line.
Dolnick BJ; Black AR
Cancer Res; 1996 Jul; 56(14):3207-10. PubMed ID: 8764108
[TBL] [Abstract][Full Text] [Related]
32. Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture.
Glazer RI; Lloyd LS
Mol Pharmacol; 1982 Mar; 21(2):468-73. PubMed ID: 7099147
[TBL] [Abstract][Full Text] [Related]
33. Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure.
McGuire JJ; Haile WH; Russell CA; Galvin JM; Shane B
Oncol Res; 1995; 7(10-11):535-43. PubMed ID: 8866666
[TBL] [Abstract][Full Text] [Related]
34. Interferon and the incorporation of 5-fluorouracil into RNA of normal tissues and a secondary liver carcinoma in rat.
Roos G; Stenram U
Anticancer Res; 1994; 14(2A):379-82. PubMed ID: 7517119
[TBL] [Abstract][Full Text] [Related]
35. Molecular cloning and characterization of the complementary DNA for the M(r) 85,000 protein overexpressed in adriamycin-resistant human tumor cells.
Sugimoto Y; Hamada H; Tsukahara S; Noguchi K; Yamaguchi K; Sato M; Tsuruo T
Cancer Res; 1993 Jun; 53(11):2538-43. PubMed ID: 8495417
[TBL] [Abstract][Full Text] [Related]
36. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
[TBL] [Abstract][Full Text] [Related]
37. 5-Fluorouracil suppresses nitric oxide biosynthesis in colon carcinoma cells.
Jin Y; Heck DE; DeGeorge G; Tian Y; Laskin JD
Cancer Res; 1996 May; 56(9):1978-82. PubMed ID: 8616835
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of sensitivity and resistance of murine tumors to 5-fluorouracil.
Ardalan B; Cooney DA; Jayaram HN; Carrico CK; Glazer RI; Macdonald J; Schein PS
Cancer Res; 1980 May; 40(5):1431-7. PubMed ID: 6245793
[TBL] [Abstract][Full Text] [Related]
39. Thymidine enhancement of methotrexate and 5-fluorouracil toxicity in cultured human colon carcinoma.
Benz C; Choti M; Newcomer L; Cadman E
Cancer Chemother Pharmacol; 1984; 12(2):104-10. PubMed ID: 6199130
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of cross-resistance to methotrexate and 5-fluorouracil in an A2780 human ovarian carcinoma cell subline resistant to cisplatin.
Newman EM; Lu Y; Kashani-Sabet M; Kesavan V; Scanlon KJ
Biochem Pharmacol; 1988 Feb; 37(3):443-7. PubMed ID: 3337743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
